Security key
03969K108
Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT)
CUSIP: 03969K108
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 132,368,934
- Total 13F value
- $3,118,364,582
- Share change
- +2,592,121
- Put/Call ratio
- 25%
- SEC-reported price per share
- $23.56
- Number of holders
- 269
- Value change
- +$53,161,810
- Number of buys
- 135
- Number of sells
- 132
- Shares outstanding
- 123,890,213
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
269
Top holders
10
ARQT full security history
Ownership snapshot
Full 13F holder table
Arcutis Biotherapeutics, Inc. SEC filings
Arcutis Biotherapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ARQT - Arcutis Biotherapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences VII...
Disclosed value leader
SUVRETTA CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 7.5%
13D/G row: Frazier Life Sciences VIII, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences VIII, L.P. leads the comparable SEC ownership view at 7.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences VIII, L.P.'s linked filing trail.
Comparable ownership
Top 5
Frazier Life Sciences VIII, L.P.
7.5%
Rubric Capital Management LP
6.8%
PRUDENTIAL FINANCIAL INC
4.3%
Polar Capital Holdings Plc
4.2%
JENNISON ASSOCIATES LLC
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences VIII, L.P. |
13D/G
3/4/5
Patrick J. Heron · 10%+ Owner
|
7.5%
|
$130,399,321
8,943,712 shares
|
$0 | 18 Aug 2025 |
| Rubric Capital Management LP |
13F
13D/G
Company
|
6.8%
from 13D/G
|
$240,206,596
8,271,577 shares
|
— | 31 Dec 2025 |
| PRUDENTIAL FINANCIAL INC |
13D/G
13F
Company
|
4.3%
|
$127,901,438
5,302,713 shares
|
-$42,866,378 | 31 Mar 2026 |
| Polar Capital Holdings Plc |
13F
13D/G
Company
|
4.2%
from 13D/G
|
$161,351,148
5,556,169 shares
|
— | 31 Dec 2025 |
| JENNISON ASSOCIATES LLC |
13F
13D/G
Company
|
4%
from 13D/G
|
$196,252,495
6,758,006 shares
|
— | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
Company
|
9.7%
|
$347,434,560
11,964,000 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
269
Shares
132,368,934
Rows available
269
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
269
Q1 2026 holders
269
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|